S&P 500   3,275.40 (+1.19%)
DOW   27,053.29 (+1.08%)
QQQ   267.83 (+1.39%)
AAPL   109.72 (+2.43%)
MSFT   205.29 (+2.34%)
FB   250.24 (+0.49%)
GOOGL   1,428.30 (+1.34%)
AMZN   3,051.73 (+1.73%)
NVDA   500.83 (+3.27%)
TSLA   396.52 (+4.25%)
BABA   270.86 (-0.77%)
CGC   14.54 (-0.41%)
GE   6.15 (+0.65%)
MU   50.19 (+0.68%)
AMD   76.62 (+2.53%)
T   28.20 (+1.18%)
F   6.74 (+1.51%)
ACB   5.31 (+2.71%)
GILD   62.22 (-1.38%)
NFLX   473.88 (+0.69%)
DIS   123.66 (+0.31%)
BAC   23.73 (+2.02%)
BA   148.44 (-1.81%)
S&P 500   3,275.40 (+1.19%)
DOW   27,053.29 (+1.08%)
QQQ   267.83 (+1.39%)
AAPL   109.72 (+2.43%)
MSFT   205.29 (+2.34%)
FB   250.24 (+0.49%)
GOOGL   1,428.30 (+1.34%)
AMZN   3,051.73 (+1.73%)
NVDA   500.83 (+3.27%)
TSLA   396.52 (+4.25%)
BABA   270.86 (-0.77%)
CGC   14.54 (-0.41%)
GE   6.15 (+0.65%)
MU   50.19 (+0.68%)
AMD   76.62 (+2.53%)
T   28.20 (+1.18%)
F   6.74 (+1.51%)
ACB   5.31 (+2.71%)
GILD   62.22 (-1.38%)
NFLX   473.88 (+0.69%)
DIS   123.66 (+0.31%)
BAC   23.73 (+2.02%)
BA   148.44 (-1.81%)
S&P 500   3,275.40 (+1.19%)
DOW   27,053.29 (+1.08%)
QQQ   267.83 (+1.39%)
AAPL   109.72 (+2.43%)
MSFT   205.29 (+2.34%)
FB   250.24 (+0.49%)
GOOGL   1,428.30 (+1.34%)
AMZN   3,051.73 (+1.73%)
NVDA   500.83 (+3.27%)
TSLA   396.52 (+4.25%)
BABA   270.86 (-0.77%)
CGC   14.54 (-0.41%)
GE   6.15 (+0.65%)
MU   50.19 (+0.68%)
AMD   76.62 (+2.53%)
T   28.20 (+1.18%)
F   6.74 (+1.51%)
ACB   5.31 (+2.71%)
GILD   62.22 (-1.38%)
NFLX   473.88 (+0.69%)
DIS   123.66 (+0.31%)
BAC   23.73 (+2.02%)
BA   148.44 (-1.81%)
S&P 500   3,275.40 (+1.19%)
DOW   27,053.29 (+1.08%)
QQQ   267.83 (+1.39%)
AAPL   109.72 (+2.43%)
MSFT   205.29 (+2.34%)
FB   250.24 (+0.49%)
GOOGL   1,428.30 (+1.34%)
AMZN   3,051.73 (+1.73%)
NVDA   500.83 (+3.27%)
TSLA   396.52 (+4.25%)
BABA   270.86 (-0.77%)
CGC   14.54 (-0.41%)
GE   6.15 (+0.65%)
MU   50.19 (+0.68%)
AMD   76.62 (+2.53%)
T   28.20 (+1.18%)
F   6.74 (+1.51%)
ACB   5.31 (+2.71%)
GILD   62.22 (-1.38%)
NFLX   473.88 (+0.69%)
DIS   123.66 (+0.31%)
BAC   23.73 (+2.02%)
BA   148.44 (-1.81%)
Log in
NASDAQ:NVUS

Novus Therapeutics Competitors

$0.92
-0.05 (-5.05 %)
(As of 09/24/2020 01:18 PM ET)
Add
Compare
Today's Range
$0.88
Now: $0.92
$0.97
50-Day Range
$0.38
MA: $0.51
$1.11
52-Week Range
$0.25
Now: $0.92
$1.45
Volume24,806 shs
Average Volume1.74 million shs
Market Capitalization$17.84 million
P/E RatioN/A
Dividend YieldN/A
Beta3.12

Competitors

Novus Therapeutics (NASDAQ:NVUS) Vs. DMAC, MRKR, NOVN, TRVI, CLSD, and EDSA

Should you be buying NVUS stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Novus Therapeutics, including DiaMedica Therapeutics (DMAC), TapImmune (MRKR), Novan (NOVN), Trevi Therapeutics (TRVI), Clearside Biomedical (CLSD), and Edesa Biotech (EDSA).

Novus Therapeutics (NASDAQ:NVUS) and DiaMedica Therapeutics (NASDAQ:DMAC) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, risk, profitability, valuation, analyst recommendations and earnings.

Analyst Ratings

This is a breakdown of current recommendations for Novus Therapeutics and DiaMedica Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Novus Therapeutics02102.33
DiaMedica Therapeutics00303.00

Novus Therapeutics currently has a consensus target price of $1.95, indicating a potential upside of 111.91%. DiaMedica Therapeutics has a consensus target price of $14.3333, indicating a potential upside of 269.42%. Given DiaMedica Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe DiaMedica Therapeutics is more favorable than Novus Therapeutics.

Valuation & Earnings

This table compares Novus Therapeutics and DiaMedica Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novus TherapeuticsN/AN/A$-16,010,000.00($1.20)-0.77
DiaMedica Therapeutics$500,000.00145.41$-10,650,000.00($0.89)-4.36

DiaMedica Therapeutics has higher revenue and earnings than Novus Therapeutics. DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than Novus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Novus Therapeutics and DiaMedica Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Novus TherapeuticsN/A-145.07%-126.53%
DiaMedica TherapeuticsN/A-93.84%-83.62%

Institutional and Insider Ownership

31.4% of Novus Therapeutics shares are held by institutional investors. Comparatively, 16.2% of DiaMedica Therapeutics shares are held by institutional investors. 5.6% of Novus Therapeutics shares are held by company insiders. Comparatively, 12.6% of DiaMedica Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

Novus Therapeutics has a beta of 3.12, suggesting that its share price is 212% more volatile than the S&P 500. Comparatively, DiaMedica Therapeutics has a beta of 2.43, suggesting that its share price is 143% more volatile than the S&P 500.

Summary

DiaMedica Therapeutics beats Novus Therapeutics on 9 of the 12 factors compared between the two stocks.

TapImmune (NASDAQ:MRKR) and Novus Therapeutics (NASDAQ:NVUS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and valuation.

Institutional & Insider Ownership

30.5% of TapImmune shares are held by institutional investors. Comparatively, 31.4% of Novus Therapeutics shares are held by institutional investors. 30.9% of TapImmune shares are held by company insiders. Comparatively, 5.6% of Novus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares TapImmune and Novus Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TapImmune$210,000.00344.09$-21,430,000.00($0.47)-3.30
Novus TherapeuticsN/AN/A$-16,010,000.00($1.20)-0.77

Novus Therapeutics has lower revenue, but higher earnings than TapImmune. TapImmune is trading at a lower price-to-earnings ratio than Novus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings for TapImmune and Novus Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
TapImmune02402.67
Novus Therapeutics02102.33

TapImmune presently has a consensus target price of $8.4167, indicating a potential upside of 443.01%. Novus Therapeutics has a consensus target price of $1.95, indicating a potential upside of 111.91%. Given TapImmune's stronger consensus rating and higher possible upside, equities research analysts plainly believe TapImmune is more favorable than Novus Therapeutics.

Profitability

This table compares TapImmune and Novus Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
TapImmuneN/A-56.31%-49.41%
Novus TherapeuticsN/A-145.07%-126.53%

Risk and Volatility

TapImmune has a beta of 0.79, suggesting that its share price is 21% less volatile than the S&P 500. Comparatively, Novus Therapeutics has a beta of 3.12, suggesting that its share price is 212% more volatile than the S&P 500.

Summary

TapImmune beats Novus Therapeutics on 8 of the 12 factors compared between the two stocks.

Novan (NASDAQ:NOVN) and Novus Therapeutics (NASDAQ:NVUS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, risk and earnings.

Earnings & Valuation

This table compares Novan and Novus Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novan$4.90 million14.11$-30,640,000.00($0.80)-0.63
Novus TherapeuticsN/AN/A$-16,010,000.00($1.20)-0.77

Novus Therapeutics has lower revenue, but higher earnings than Novan. Novus Therapeutics is trading at a lower price-to-earnings ratio than Novan, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Novan and Novus Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Novan-378.10%N/A-46.52%
Novus TherapeuticsN/A-145.07%-126.53%

Institutional and Insider Ownership

3.0% of Novan shares are owned by institutional investors. Comparatively, 31.4% of Novus Therapeutics shares are owned by institutional investors. 3.0% of Novan shares are owned by company insiders. Comparatively, 5.6% of Novus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Novan and Novus Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Novan01102.50
Novus Therapeutics02102.33

Novan presently has a consensus target price of $1.00, indicating a potential upside of 98.85%. Novus Therapeutics has a consensus target price of $1.95, indicating a potential upside of 111.91%. Given Novus Therapeutics' higher possible upside, analysts plainly believe Novus Therapeutics is more favorable than Novan.

Volatility and Risk

Novan has a beta of -0.26, suggesting that its stock price is 126% less volatile than the S&P 500. Comparatively, Novus Therapeutics has a beta of 3.12, suggesting that its stock price is 212% more volatile than the S&P 500.

Summary

Novus Therapeutics beats Novan on 7 of the 12 factors compared between the two stocks.

Novus Therapeutics (NASDAQ:NVUS) and Trevi Therapeutics (NASDAQ:TRVI) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, risk, analyst recommendations and institutional ownership.

Institutional & Insider Ownership

31.4% of Novus Therapeutics shares are owned by institutional investors. Comparatively, 73.3% of Trevi Therapeutics shares are owned by institutional investors. 5.6% of Novus Therapeutics shares are owned by company insiders. Comparatively, 47.3% of Trevi Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Novus Therapeutics and Trevi Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Novus Therapeutics02102.33
Trevi Therapeutics01302.75

Novus Therapeutics currently has a consensus price target of $1.95, indicating a potential upside of 111.91%. Trevi Therapeutics has a consensus price target of $11.00, indicating a potential upside of 187.96%. Given Trevi Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Trevi Therapeutics is more favorable than Novus Therapeutics.

Earnings & Valuation

This table compares Novus Therapeutics and Trevi Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novus TherapeuticsN/AN/A$-16,010,000.00($1.20)-0.77
Trevi TherapeuticsN/AN/A$-26,050,000.00($2.28)-1.68

Trevi Therapeutics is trading at a lower price-to-earnings ratio than Novus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Novus Therapeutics and Trevi Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Novus TherapeuticsN/A-145.07%-126.53%
Trevi TherapeuticsN/A-58.90%-52.38%

Risk and Volatility

Novus Therapeutics has a beta of 3.12, meaning that its share price is 212% more volatile than the S&P 500. Comparatively, Trevi Therapeutics has a beta of 0.11, meaning that its share price is 89% less volatile than the S&P 500.

Summary

Trevi Therapeutics beats Novus Therapeutics on 7 of the 11 factors compared between the two stocks.

Clearside Biomedical (NASDAQ:CLSD) and Novus Therapeutics (NASDAQ:NVUS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, dividends, risk, profitability, analyst recommendations and institutional ownership.

Institutional and Insider Ownership

25.5% of Clearside Biomedical shares are held by institutional investors. Comparatively, 31.4% of Novus Therapeutics shares are held by institutional investors. 13.1% of Clearside Biomedical shares are held by company insiders. Comparatively, 5.6% of Novus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Clearside Biomedical and Novus Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Clearside Biomedical-280.03%-189.40%-76.70%
Novus TherapeuticsN/A-145.07%-126.53%

Valuation & Earnings

This table compares Clearside Biomedical and Novus Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Clearside Biomedical$2.17 million32.03$-30,770,000.00($0.81)-1.85
Novus TherapeuticsN/AN/A$-16,010,000.00($1.20)-0.77

Novus Therapeutics has lower revenue, but higher earnings than Clearside Biomedical. Clearside Biomedical is trading at a lower price-to-earnings ratio than Novus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent recommendations for Clearside Biomedical and Novus Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Clearside Biomedical02302.60
Novus Therapeutics02102.33

Clearside Biomedical currently has a consensus target price of $5.75, indicating a potential upside of 285.91%. Novus Therapeutics has a consensus target price of $1.95, indicating a potential upside of 111.91%. Given Clearside Biomedical's stronger consensus rating and higher possible upside, equities analysts plainly believe Clearside Biomedical is more favorable than Novus Therapeutics.

Volatility and Risk

Clearside Biomedical has a beta of 0.94, meaning that its stock price is 6% less volatile than the S&P 500. Comparatively, Novus Therapeutics has a beta of 3.12, meaning that its stock price is 212% more volatile than the S&P 500.

Summary

Clearside Biomedical beats Novus Therapeutics on 7 of the 13 factors compared between the two stocks.

Edesa Biotech (NASDAQ:EDSA) and Novus Therapeutics (NASDAQ:NVUS) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations and earnings.

Volatility & Risk

Edesa Biotech has a beta of 0.92, indicating that its share price is 8% less volatile than the S&P 500. Comparatively, Novus Therapeutics has a beta of 3.12, indicating that its share price is 212% more volatile than the S&P 500.

Insider & Institutional Ownership

0.2% of Edesa Biotech shares are held by institutional investors. Comparatively, 31.4% of Novus Therapeutics shares are held by institutional investors. 61.4% of Edesa Biotech shares are held by insiders. Comparatively, 5.6% of Novus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Edesa Biotech and Novus Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Edesa Biotech00103.00
Novus Therapeutics02102.33

Novus Therapeutics has a consensus target price of $1.95, indicating a potential upside of 111.91%. Given Novus Therapeutics' higher probable upside, analysts clearly believe Novus Therapeutics is more favorable than Edesa Biotech.

Earnings & Valuation

This table compares Edesa Biotech and Novus Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Edesa Biotech$210,000.00335.32$-5,030,000.00N/AN/A
Novus TherapeuticsN/AN/A$-16,010,000.00($1.20)-0.77

Edesa Biotech has higher revenue and earnings than Novus Therapeutics.

Profitability

This table compares Edesa Biotech and Novus Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Edesa Biotech-717.73%-96.39%-73.51%
Novus TherapeuticsN/A-145.07%-126.53%

Summary

Edesa Biotech beats Novus Therapeutics on 6 of the 11 factors compared between the two stocks.

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
DMAC
DiaMedica Therapeutics
1.1$3.88-1.5%$73.83 million$500,000.00-5.04
MRKR
TapImmune
1.1$1.55-0.0%$72.26 million$210,000.00-3.04
Novan logo
NOVN
Novan
1.2$0.50-4.4%$72.20 million$4.90 million-1.05
TRVI
Trevi Therapeutics
1.5$3.82-2.6%$71.50 millionN/A-2.56
Clearside Biomedical logo
CLSD
Clearside Biomedical
1.9$1.50-2.0%$70.90 million$2.17 million-3.41Heavy News Reporting
EDSA
Edesa Biotech
0.8$7.48-0.3%$70.23 million$210,000.00-12.68
ONCY
Oncolytics Biotech
1.2$1.67-0.6%$69.16 millionN/A-2.06Heavy News Reporting
MREO
Mereo BioPharma Group
0.5$2.72-1.8%$68.97 millionN/A-1.09Upcoming Earnings
Heavy News Reporting
ETTX
Entasis Therapeutics
2.1$2.27-9.7%$67.96 million$7 million-0.70
IMMUTEP LTD/S logo
IMMP
IMMUTEP LTD/S
1.1$1.76-3.4%$66.30 million$4.92 million0.00Analyst Report
Synlogic logo
SYBX
Synlogic
1.7$1.98-2.5%$65.94 million$2.22 million-1.19
ENLV
Enlivex Therapeutics
1.3$4.81-1.5%$65.53 millionN/A-5.94
Oramed Pharmaceuticals logo
ORMP
Oramed Pharmaceuticals
1.3$2.82-1.8%$65.17 million$2.70 million-8.55Analyst Revision
KITOV PHARMA LT/S logo
KTOV
KITOV PHARMA LT/S
1.4$4.08-0.2%$64.00 million$1 million-1.36
Savara logo
SVRA
Savara
1.6$1.14-3.5%$63.87 millionN/A-0.79
Eyenovia logo
EYEN
Eyenovia
1.7$3.03-2.3%$63.66 millionN/A-2.61
Aridis Pharmaceuticals logo
ARDS
Aridis Pharmaceuticals
1.3$6.78-2.4%$63.62 million$1.02 million-2.51
Infinity Pharmaceuticals logo
INFI
Infinity Pharmaceuticals
1.3$1.03-4.9%$63.58 million$3.05 million-1.37
ASLAN PHARMACEU/ADR logo
ASLN
ASLAN PHARMACEU/ADR
1.1$1.68-14.3%$61.54 million$3 million-1.54
Citius Pharmaceuticals logo
CTXR
Citius Pharmaceuticals
1.5$0.96-7.0%$58.25 millionN/A-1.20Upcoming Earnings
Adamis Pharmaceuticals logo
ADMP
Adamis Pharmaceuticals
1.4$0.71-4.8%$56.92 million$22.11 million-1.41Analyst Report
Proteostasis Therapeutics logo
PTI
Proteostasis Therapeutics
1.2$1.05-1.9%$55.83 million$5 million-1.25
Soligenix logo
SNGX
Soligenix
1.4$1.79-2.8%$54.92 million$4.60 million-2.56
MNPR
Monopar Therapeutics
1.5$5.01-0.8%$53.41 millionN/A-11.13Analyst Report
Aileron Therapeutics logo
ALRN
Aileron Therapeutics
1.3$1.24-0.8%$52.22 millionN/A-1.35
Diffusion Pharmaceuticals logo
DFFN
Diffusion Pharmaceuticals
1.2$0.78-3.7%$51.84 millionN/A-0.44
KemPharm logo
KMPH
KemPharm
2.0$0.71-1.4%$51.45 million$12.84 million-1.25
Recro Pharma logo
REPH
Recro Pharma
1.8$2.14-0.5%$50.83 million$99.22 million10.70
Moleculin Biotech logo
MBRX
Moleculin Biotech
1.2$0.76-7.9%$50.60 millionN/A-2.11
Merrimack Pharmaceuticals logo
MACK
Merrimack Pharmaceuticals
1.4$3.83-1.8%$50.31 millionN/A0.00Heavy News Reporting
Cumberland Pharmaceuticals logo
CPIX
Cumberland Pharmaceuticals
2.4$3.16-2.5%$49.81 million$47.53 million-9.88
Vascular Biogenics logo
VBLT
Vascular Biogenics
1.3$1.15-2.6%$49.48 million$560,000.00-1.95
MITO
Stealth BioTherapeutics
1.3$1.36-2.6%$48.87 million$21.09 million68.03Heavy News Reporting
Conatus Pharmaceuticals logo
CNAT
Conatus Pharmaceuticals
0.7$1.47-5.4%$48.76 million$21.72 million-4.90
SCYNEXIS logo
SCYX
SCYNEXIS
1.4$4.59-0.2%$48.55 million$120,000.00-0.93
Onconova Therapeutics logo
ONTX
Onconova Therapeutics
1.3$0.28-1.8%$48.53 million$2.18 million-0.18
ZOM
Zomedica Pharmaceuticals Corp (NYSEAMERICAN)
1.9$0.08-1.2%$48.40 millionN/A-0.85
KZIA
Kazia Therapeutics
0.4$6.70-0.9%$48.35 million$1.12 million-5.36
APM
Aptorum Group
0.5$1.29-11.6%$46.65 million$540,000.000.00
Vistagen Therapeutics logo
VTGN
Vistagen Therapeutics
1.2$0.59-1.4%$45.63 millionN/A-1.24
Pulmatrix logo
PULM
Pulmatrix
1.3$1.08-10.2%$40.94 million$7.91 million-1.71Analyst Report
Forward Pharma A/S logo
FWP
Forward Pharma A/S
0.7$5.97-1.0%$40.91 million$1.25 billion0.00
IMMURON LTD/S logo
IMRN
IMMURON LTD/S
0.5$7.17-1.5%$40.78 million$1.69 million0.00
PRPH
ProPhase Labs
0.4$3.26-1.8%$38.53 million$9.88 million0.00Heavy News Reporting
VCNX
Vaccinex
1.9$1.75-6.3%$37.38 million$520,000.00-0.98Analyst Downgrade
Unusual Options Activity
Heavy News Reporting
Bellicum Pharmaceuticals logo
BLCM
Bellicum Pharmaceuticals
1.3$6.34-5.8%$36.68 million$7.14 million-0.32
PDSB
PDS Biotechnology
1.4$2.26-5.3%$36.56 millionN/A-0.90Heavy News Reporting
AGE
AgeX Therapeutics
0.5$0.84-4.8%$33.22 million$1.73 million-2.62
ANVS
Annovis Bio
1.4$4.51-3.3%$32.05 millionN/A0.00
Cellectar Biosciences logo
CLRB
Cellectar Biosciences
1.4$1.19-0.8%$31.96 millionN/A-0.83
This page was last updated on 9/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.